Thermalin Diabetes, LLC

Cleveland, OH 44106

SBIR Award Summary

Total Number of Awards 16
Total Value of Awards $9.71MM
First Award Date 09/30/09
Most Recent Award Date 09/19/16

Key Personnel

Last Name Name Awards Contact
Frank Bruce Hill Frank 15
Weiss Michael Aaron Weiss 1

16 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: RFA-DK-15-022
Budget: 09/19/16 - 08/31/17

Project Summary We seek to develop an ultra-stable ultra-fast insulin analog formulation for use in advanced ?smart? pumps in the treatment of diabetes mellitus. A commercially available insulin formulation that is stable at body temperature for at least 180 days and at room temperature for a year would respectively make practical (a) implantab...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 09/09/15 - 08/31/16

DESCRIPTION (provided by applicant): Insulin is essential to the treatment of Type 1 diabetes mellitus (DM) and is often required for optimal management of Type 2 DM. Despite its many decades of clinical use, the complex post-receptor signaling properties of insulin include both therapeutic and non-therapeutic effects. The overarching objective ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-13-088
Budget: 05/01/15 - 04/30/16

DESCRIPTION (provided by applicant): In this Phase 2 SBIR application we seek to advance toward human clinical trials a rapid-acting and ultra- concentrated monomeric insulin analog of novel halogen-based protein design. Designated Fluorolog, this analog was found in Phase I studies to exhibit rapid-acting PK/PD properties irrespective of protei...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-13-234
Budget: 09/24/14 - 09/23/15

DESCRIPTION (provided by applicant): Pre-mixed formulations of soluble prandial insulin analogs and NPH micro-crystalline suspensions provide a simplified and cost-effective basal-bolus regimen for patients with Type 2 diabetes mellitus (T2DM) not effectively controlled by basal insulin therapy alone. Such twice-daily products (in vials or pre-f...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-13-088
Budget: 05/15/14 - 04/30/15

Project Summary In this Phase 2 SBIR application we seek to advance toward human clinical trials a rapid-acting and ultra- concentrated monomeric insulin analog of novel halogen-based protein design. Designated Fluorolog, this analog was found in Phase I studies to exhibit rapid-acting PK/PD properties irrespective of protein concentration in t...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-096
Budget: 04/01/14 - 03/31/15

DESCRIPTION (provided by applicant): We seek to develop a novel insulin analog to enhance the safety and efficacy of insulin pump therapy with broad application to the Artificial Pancreas Project ("smart pumps"). A proprietary approach is proposed based on the favorable physico-chemical properties conferred by chloro-aromatic substitutions in th...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-12-088
Budget: 09/01/13 - 08/31/14

DESCRIPTION (provided by applicant): Close-loop systems of insulin delivery-comprising an insulin pump, continuous glucose monitor, and feedback-based control algorithm-provide a promising technology to enable tight glycemic control in Type 1 diabetes mellitus with improved patient convenience and compliance. The safety and efficacy of such coup...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-12-088
Budget: 09/01/13 - 08/31/14

DESCRIPTION (provided by applicant): We seek to develop a rapid-acting U-500 insulin analog formulation for patients with Type 2 and Type 1 diabetes mellitus (T2DM and T1DM). Such a novel product would improve treatment in two contexts: (i) for T2DM patients with marked insulin resistance (as associated with "diabesity," secondary to corticoster...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-096
Budget: 06/01/13 - 05/31/14

DESCRIPTION (provided by applicant): We seek to develop an ultra-fast insulin analog formulation for the treatment of diabetes mellitus. Ultra-fast pharmacokinetic/dynamic (PK/PD) promises to enable superior performance of pump therapy (continuous subcutaneous insulin infusion;CSII) with enhanced safety and more robust integration with continuou...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-096
Budget: 04/01/13 - 03/31/14

DESCRIPTION (provided by applicant): We seek to develop a novel insulin analog to enhance the safety and efficacy of insulin pump therapy with broad application to the Artificial Pancreas Project ("smart pumps"). A proprietary approach is proposed based on the favorable physico-chemical properties conferred by chloro-aromatic substitutions in th...

Load More